[Current therapy of myasthenia gravis. I. Specific symptomatic therapy].
D000549:Ambenonium Chloride / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000009:adverse effects; D004491:Edrophonium; D004750:Enteral Nutrition; D004809:Ephedrine / Q000627:therapeutic use; D006801:Humans; D009157:Myasthenia Gravis / Q000145:classification / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy / Q000628:therapy*; D009388:Neostigmine / Q000627:therapeutic use; D026741:Physical Therapy Modalities; D011729:Pyridostigmine Bromide / Q000627:therapeutic use; D012131:Respiratory Insufficiency / Q000209:etiology; D013566:Sympathomimetics / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D013566:Sympathomimetics; D009388:Neostigmine; D000549:Ambenonium Chloride; D004491:Edrophonium; D004809:Ephedrine; D011729:Pyridostigmine Bromide
Aktuelle Therapie der Myasthenis gravia. I. Die spezifisch-symptomatische Behandlung.